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This study reveals a plausible connec-
tion between UV radiation, the lipid
mediator PAF and chromatin patterns in
immune cells of the skin. Although trans-
criptional regulation of gene expression
is commonly associated with histone
modiﬁcations, the profound effect of
PAF on several epigenetic regulators in
mast cells is noteworthy. It would be
interesting to investigate other genes that
may be regulated by PAF and to deter-
mine how epigenetic modulation,
including histone methylation, is
involved. Several other outstanding ques-
tions remain as well. They include the
signaling route from the G-protein
coupled receptor to which PAF binds
on mast cells to the induction of histone
modiﬁcations and binding of transcrip-
tion factors at the CXCR4 promoter
region. The cell-based assays performed
in this study also raise the question how
modulation of histone modifying
enzymes and epigenetic regulation of
CXCR4 in particular would impact on
mast cell migration, UV-induced immu-
nosuppression and skin carcinogenesis
in vivo. It is now increasingly recognized
that environmental stimuli can impact
on the epigenome of cells. The demon-
stration of PAF as a mediator of an
environmental factor that induces epige-
netic mechanisms of transcriptional reg-
ulation could be used as a model for
further study. Moreover, the identiﬁcation
of an epigenetic dimension operative in
photocarcinogenesis may provide further
opportunities for developing strategies to
prevent skin cancer.
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Mutational Heterogeneity in
Melanoma: An Inconvenient Truth
Gregory A. Chang1,2 and David Polsky1,2
Identiﬁcation of oncogenic BRAF mutations in primary and metastatic melano-
mas supports a linear model of clonal evolution in cancer. Some mutational
studies, however, have failed to identify BRAF mutations in metastatic tumors
from patients with BRAFmutant primary melanomas. Using a combination of
methods, Riveiro-Falkenbach et al. (2015) assert that technical issues, and not
clonal heterogeneity, may explain prior discordant mutational results.
Journal of Investigative Dermatology (2015) 135, 2913–2918. doi:10.1038/jid.2015.351
Clonal evolution of cancers, proposed
in 1976 by Nowell (1976), states that
malignant tumors are genetically
unstable, producing clonal variants with
mutations that are either favorable or
unfavorable for cell survival. This linear
evolution model predicts that metastatic
and drug-resistant clones result from an
accumulation of several favorable muta-
tions, including the original initiating
mutation. With this conceptual frame-
work, a linear model of melanoma
tumorigenesis, beginning with the
development of a BRAFmutant nevus,
followed by additional genetic and
epigenetic alterations leads to primary
melanoma and ultimately to BRAFmutant
metastatic disease. This model makes
sense for BRAFmutant melanoma.
Evidence for BRAF mutational
heterogeneity in melanoma
Although the ﬁndings of many studies
are consistent with the model described
above, several have failed to identify
conservation of BRAF mutations in all
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tumor samples analyzed from indivi-
dual patients (i.e., inter-tumor hetero-
geneity), results that challenge Nowell’s
(1976) model (Table 1). For example,
Saint-Jean et al. (2014) found inter-
tumor heterogeneity in 10/74 (14%)
patients with primary-metastatic tumor
pairs and in 8/43 (19%) patients with
more than 2 metastases. Colombino
et al. (2012) found that of the 20/99
(20%) cases of inter-tumor heterogene-
ity, 8/20 (40%) had a mutant primary
tumor but wild-type metastases, a ﬁnd-
ing inconsistent with Nowell’s model.
Similarly, Heinzerling et al. (2013)
identiﬁed 10/53 (19%) patients that
had discordant BRAFV600E mutational
results when multiple tumors were
analyzed using pyrosequencing. Of
those 10 patients, 4 exhibited mutant
primary tumors with wild-type metas-
tases (Heinzerling et al., 2013). Using a
BRAFV600E mutation-speciﬁc PCR assay
we found that 2/18 (11%) patients
had BRAFmutant primary tumors and
BRAFwild-type metastases (Yancovitz
et al., 2012). In addition, 5/19 (26%)
patients with multiple metastases
exhibited inter-tumor heterogeneity for
the BRAF mutation. We also reported
ﬁndings of intra-tumor heterogeneity.
Using laser microdissection to analyze
tumor cells isolated from separate regions
of individual primary melanomas, we
found that 6/9 (67%) primary melanomas
demonstrated substantial variation in the
relative abundance of BRAFV600E DNA in
different tumor regions. Lin et al. (2011)
also found evidence of intra-tumor
heterogeneity in primary and metastatic
tumors using several methods to identify
BRAF mutations, including analysis
of isolated single melanoma cells,
mutation-speciﬁc PCR assays, or bacter-
ial subcloning and sequencing. The
most telling evidence of heterogeneity,
however, comes from studies that found
both NRAS and BRAF mutant alleles in
multiple tumors from the same patient
(prior to the advent of BRAF inhibitor
therapy) or from the same tumor itself.
Colombino et al. (2012) identiﬁed
two patients with an NRASmutant
primary melanoma and a BRAFmutant
metastasis. Sensi et al. (2006) isolated
(via limited dilution cloning) separate
BRAFV600E and NRASQ61R mutant
melanoma cells from a short-term
culture of an NRASmutant subcutaneous
metastasis providing direct evidence
that patient tumors may contain unique
clonal subpopulations. Recently,
Eriksson et al. (2015) identiﬁed 4
patients with BRAFV600E primary
melanomas and BRAFwild-type or
BRAFnon-V600E mutant metastases. Two
of the BRAFwild-type metastases had
NRAS mutations.
Mutational heterogeneity,
a feature of tumor evolu-
tion models, challenges
current treatment strate-
gies for melanoma.
These reports demonstrating inter-
and intra-tumor mutational heterogene-
ity can be accommodated in Nowell’s
tumor evolution paradigm when one
considers the modiﬁcations described
in 1982 by Fidler and Hart (1982). They
noted that primary tumors are hetero-
geneous, polyclonal neoplasms com-
prised of tumor cell subpopulations
with varying biological characteristics,
including metastatic potentials. As such,
more than one subclone may have the
ability to form metastases, which could
explain the ﬁndings described above,
assuming that BRAF mutations are not
required for metastatic spread of
melanoma. Further support for the
polyclonality of human tumors is evi-
denced by the different organotropisms
of metastatic disease, a prominent
feature of melanoma and other
malignancies (Figure 1). Currently, this
polyclonal model of cancer best
explains discordant inter- and intra-
tumor mutational results and the orga-
notropic characteristics of melanoma
metastases.
Challenging the concept of mutational
heterogeneity
In the current issue, this concept is
challenged by Riveiro-Falkenbach et al.
(2015). They use immunohistochemistry
(IHC) to compare expression of mutant
BRAFV600E to DNA-based BRAFV600
mutation detection in paired primary
and metastatic melanomas from 140
patients. The Ventana VE1 anti-
BRAFV600E antibody (Ventana Medical
Systems, Tucson, AZ) was used to
conduct the IHC analysis. Two DNA-
based methods were used: the cobas
4800 BRAFV600 Mutation Test, and
Sanger sequencing.
The cobas 4800 BRAFV600 Mutation
Test is a Taqman-based real-time PCR
mutation assay used to detect V600
mutations in formalin-ﬁxed, parafﬁn-
embedded human melanoma tissue.
The test mainly detects V600E but is
known to cross-react with V600K/D.
This FDA-approved test is part of the
standard of care for melanoma patients
with advanced disease to determine
eligibility for BRAF inhibitor therapy:
patients with the mutation are eligible
for treatment, whereas patients lacking
the mutation are not. The manufac-
turer’s package insert states that the
cobas 4800 has an over 95% positive
detection rate in pre-clinical and clin-
ical investigations. Additional validation
studies demonstrate that the cobas 4800
test is able to detect more V600E
mutations than Sanger sequencing,
and that Sanger has more false-positive
results than cobas when using an
additional detection method to conﬁrm
results (Halait et al., 2012). Importantly,
adequate tumor content is an essential
requirement for any DNA-based muta-
tional assay (Sensi et al., 2006). In tissue
samples witho10% tumor content (i.e.,
490% normal tissue), the chances of
ﬁnding a mutation are diminished and
the cobas test often fails to attain
consistent results (Halait et al., 2012).
In addition, there always exists the
possibility of sampling error if cut
sections are not representative of a
genetically polyclonal tumor.
The monoclonal BRAFV600E mutation-
speciﬁc antibody, named VE1, binds to
an 11-amino-acid sequence in the
BRAFV600E mutant protein between
amino acids 596–606 (Capper et al.,
2011). Studies investigating VE1 have
demonstrated the high sensitivity
(80–97%) and speciﬁcity (98–100%)
of the antibody to distinguish the
V600E mutant protein from V600K/R/
Q (Capper et al., 2011; Pearlstein et al.,
2014). One of the values of IHC
analysis is that normal tissue contami-
nation, which can limit the sensitivity of
DNA-based assays, is not a major
concern. Quantifying the homogeneity
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of staining, however, can be highly
subjective. There may be difﬁculties in
identifying rare events in tissue sections
(e.g., stained or unstained single cells),
or distinguishing true staining from
artifacts such as the presence of mela-
nophages or necrotic tissue.
Overall, Riveiro-Falkenbach et al.
(2015) found that 52% of tumors had
BRAFV600 mutations according to the
cobas test. When analyzed for inter-
tumor heterogeneity of BRAF mutations
they found that 117/140 (83.6%)
primary-metastatic pairs were concor-
dant for the presence or absence of the
BRAF mutation. They used IHC on a
subset of the concordant pairs (n= 61)
and conﬁrmed that those pairs were
100% concordant using VE1. When
using IHC to test 23 cobas-discordant
primary-metastatic tumor pairs, they
found no evidence of discordance.
They suggested that IHC is more sensi-
tive than DNA-based mutation detec-
tion methods. There were several cases
of positive VE1 staining in samples with
o10% tumor content and Sanger
sequencing and cobas testing yielded
wild-type results. In addition, the high
speciﬁcity of the VE1 antibody, evi-
denced by the lack of staining in all
tumor samples harboring a V600K muta-
tion, mediates concerns of possible false-
positive results. Ultimately,Riveiro-
Falkenbach et al. (2015) conclude that
the cobas assay is less sensitive and
accurate in calling mutant positive
samples than either Sanger sequencing
or IHC, and that the existence of tumor
heterogeneity in published studies may
be owing to technical issues rather than
actual tumor heterogeneity.
Although the VE1 antibody has pro-
ven to be a highly sensitive and V600E-
speciﬁc reagent in several studies
(Capper et al., 2011; Pearlstein et al.,
2014) including Riveiro-Falkenbach
et al. (2015), their conclusions
regarding the existence (or lack
thereof) of inter-tumor heterogeneity
needs to be interpreted cautiously.
Close inspection of their results reveals
that among the 23 patients with cobas-
discordant mutational results, 5 patients
had V600K mutant tumors. These cases
should not be included among the
discordant cases as the cobas assay is
not primarily designed to detect this
mutation. Besides, these cases were
concordant using Sanger sequencing.
In addition, 1 patient had two primary
melanomas, of which the thicker one
was not tested via cobas, and it was
determined to be mutationally concor-
dant with its paired metastasis using
Sanger sequencing. Finally, there were
2 cases where the cobas test was
repeated and subsequently yielded
results concordant with other samples
from that patient. Removing these 8
cases from the analysis leaves 15 cobas-
discordant cases. Fortunately, Riveiro-
Falkenbach et al. (2015) included
Sanger sequencing as a second DNA-
based mutation detection method.
When analyzing the tumor sets for
inter-tumor heterogeneity using Sanger
sequencing, only 3/15 (20%) cases had
discordant mutational results. In all three
of the discordant cases, the discordant,
wild-type samples contained ⩽15%
tumor content prior to macrodissection.
The authors note that all samples were
macrodissected prior to DNA extraction;
however, enriching samples with very
low tumor content using macrodissec-
tion can be technically challenging as
Brain metastasis
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Figure 1. Model of primary intra-tumor heterogeneity giving rise to organotropic metastases characterized by intra- and inter-tumor heterogeneity. Fidler and
Hart (1982) note that genetic instability, as discussed by Nowell (1976), provides a mechanism for tumors to evolve in response to selective pressures. They
suggest this evolution leads to biological diversity rather than a reduction in the number of tumor subclones. Wan et al. (2013) review recent studies that suggest
that subclones within the primary tumor may possess intrinsic genotypic and phenotypic differences in their abilities to spread to different metastatic sites. The
illustration above depicts how the theories of Nowell (1976), Fidler and Hart (1982), and Wan et al. (2013) work together to model the path to polyclonality and
organ tropisms via genetic instability. Metastatic melanoma data from Hwu et al. (2003).
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this is performed on unstained sections.
It may still result in low (or no) tumor
content in the dissected sample if not
carefully performed.
If we consider VE1 IHC to be the most
sensitive V600E mutation detection
method employed in this study, then
their results suggest that Sanger sequen-
cing is more sensitive than the FDA-
approved cobas assay. This ﬁnding
contradicts previous reports that
demonstrated that the cobas assay is
more sensitive than Sanger sequencing
(Halait et al., 2012). This raises
concerns about their cobas assay
results. If we consider their Sanger
sequencing results to be the more
accurate DNA-based mutation method
in this study, we ﬁnd a lack of inter-
tumor heterogeneity among this sample
set. The authors, therefore, cannot con-
clude that prior reports of inter-tumor
heterogeneity—of which several were
based on Sanger sequencing or other
methodologies using tumor rich sam-
ples—are solely due to artifact.
With respect to intra-tumor hetero-
geneity, Riveiro-Falkenbach et al.
(2015) reported homogenous staining
of all 137 positively stained tumor
samples, and they assert that their
results provide evidence that intra-
tumoral heterogeneity does not exist.
They suggest that artifacts and necrotic
tissue may have a role in the hetero-
geneous results reported by others.
These results, in fact, contradict the
ﬁndings of other groups including
Busam et al. (2013), Heinzerling et al.
(2013) and Eriksson et al. (2015) who
demonstrated heterogeneous staining
using the same VE1 antibody. Busam
et al. (2013) found that 2/10 (20%)
superﬁcial spreading melanomas exhi-
bited focal staining of a subpopulation
within the tumor suggestive of intra-
tumoral heterogeneity. In addition, they
found that 6/22 (27%) BRAFmutant
metastases had both BRAFV600E-immu-
nopositive and -immunonegative popu-
lations within the tumor (Busam et al.,
2013). Heinzerling et al. (2013) found
strong VE1 staining in one part of a
mutation-positive lymph node whereas
adjacent tumor cells did not react with
the antibody. Eriksson et al. (2015)
described heterogeneous staining
within 10/200 (5%) tumors, most of
which were primary melanomas. Clearly,
the conclusion that all heterogeneity is
due to artifact or technical issues must be
explored in future studies.
Altogether, the ﬁndings by Riveiro-
Falkenbach et al. (2015) support the
potential use of the VE1 antibody as a
triage tool to identify the V600E mutation.
IHC negative results, however, still
require DNA testing to rule out V600K
and other rare V600 mutations, as
patients with those less common BRAF
mutations may still beneﬁt from BRAF
inhibitor therapy (Klein et al., 2013).
The inconvenient truth of tumor
heterogeneity in melanoma
Ultimately, heterogeneity with respect
to BRAF mutations is part of a larger
story when considering polyclonal var-
iations in gene expression, or analysis of
additional mutations to identify tumor
subclones. Several studies in breast,
prostate, pancreatic, and renal cancers
have contributed to the growing body of
evidence for tumor evolution leading to
biological diversity and heterogeneity.
Recent studies in melanoma using next-
generation sequencing methods have
made similar ﬁndings. Ding et al. (2014)
identiﬁed tumor subclones in 11/15
melanomas, as well as evolutionary
mutation relationships between four
anatomically separate metastases in
two different patients. They also
showed that mixed treatment res-
ponses were associated with different
subclonal populations possessing (or
not) a BRAF resistance gene mutation.
Other studies analyzing tumors
removed from patients who progressed
on BRAF inhibitor therapy have also
revealed mutational tumor hetero-
geneity. Van Allen et al. (2014) found
multiple resistance gene alterations in a
single metastatic tumor providing
evidence of continued divergent
evolution that supports Fidler and
Hart’s (1982) polyclonal model. Shi
et al. (2014) analyzed 100 metastatic
tumors from 44 patients and found that
9/44 (20%) patients had ⩾2 resistance
mechanisms in their tumors, and 13/16
(81%) patients with multiple tumors had
multiple mechanisms of resistance.
With advanced methodologies in
molecular pathology, the polyclonal
nature of malignant neoplasms including
melanoma is becoming more apparent.
Although this phenomenon may chal-
lenge our current ability to cure patients
with melanoma, additional investigations
into the mechanisms driving clonal
diversity may lead to greater understand-
ing of the molecular pathogenesis of
various melanoma subtypes and the
development of more effective therapies.
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Beyond Red Hair and Sunburns:
Uncovering the Molecular
Mechanisms of MC1R Signaling and
Repair of UV-Induced DNA Damage
Pamela B. Cassidy1, Zalfa A. Abdel-Malek2 and Sancy A. Leachman1
Scientists at the University of Kentucky are unraveling the details of DNA-
damage repair in the melanocyte, with an eye towards ﬁnding druggable targets
for melanoma prevention. Jarret et al., (2015, this issue) report in this issue three
new assays that can yield mechanistic information about nucleotide excision
repair (NER) stimulated by cAMP-dependent signaling downstream of the
melanocortin-1 receptor (MC1R).
Journal of Investigative Dermatology (2015) 135, 2918–2921. doi:10.1038/jid.2015.349
Molecularly-targeted prevention
Protecting the lives of individuals and
increasing the productivity of society by
stopping disease before it causes harm
is of the greatest aspirations of
medicine; and as the molecular etiolo-
gies of cancer are discovered, there will
be opportunities to apply targeted
molecular strategies to its prevention,
much as they have been applied to
therapeutics. Consider the development
of targeted therapy for melanoma using
BRAF inhibitors (Puzanov and Flaherty,
2010). This accomplishment resulted
directly from the elucidation of the
molecular mechanism of melanocyte
transformation (V600E mutation of
BRAF) and subsequent identiﬁcation
of a drug that could speciﬁcally
antagonize the mutated protein. To
develop targeted prevention agents, it
will be necessary to elucidate targetable
molecular pathways that predispose a
cell to transformation and then to
identify drugs that can successfully
and safely target these pathways.
Melanoma is a good candidate disease
for the development of targeted
prevention agents because several
melanoma predisposition genes have
been identiﬁed. One of the most
common and well characterized of
these is MC1R (Abdel-Malek et al.,
2014), the target of investigation in an
article from this issue by Jarrett et al.,
(2015).
MC1R and DNA-damage repair
Epidemiological studies have found a
strong correlation between the carriage
of loss-of-function mutations in MC1R
(which encodes a 7-pass transmem-
brane G-protein-coupled receptor) and
both the red-hair phenotype and mela-
noma risk (Pasquali et al., 2015). In cell
culture, treatment of melanocytes that
express the wild-type MC1R (Figure 1),
with the agonist alpha–melanocyte-sti-
mulating hormone (α-MSH), elicits a
variety of responses, including synthesis
of eumelanin, reduction of UV-induced
oxidative stress, stimulation of adenylyl
cyclase and cAMP-dependent signaling,
and enhancement of DNA repair
via base-excision repair and NER
mechanisms (Abdel-Malek et al.,
2014). NER repairs UV-photoproducts
such as cyclobutane pyrimidine
dimers and 6′-4′-pyrimdine-pyrimidone
photoproducts. If not repaired properly,
cyclobutane pyrimidine dimer forma-
tion can result in C4T transitions,
which are a signature mutation in
melanomas (discussed in (Jarrett et al.,
2014)). Thus, impaired NER in the skin
cells of individuals with loss-of-function
MC1R mutations likely contributes to
their vulnerability to melanoma, and it
is therefore a rational target for preven-
tion. Until recently, the mechanistic
details (i.e., demonstrable, quantiﬁable
and targetable molecular events) linking
MC1R activation to NER have been
hazy. Then, it was reported last year
that pre-treatment of melanocytes with
α-MSH augmented their DNA-damage
response by increasing phosphorylation
of DNA-damage sensing proteins ataxia
telangiectasia and Rad3-related protein
(ATR, at serine 428) and ataxia telan-
giectasia mutated (at serine 1981) and
enhancing formation of phosphorylated
γH2AX at nuclear sites of DNA repair
(Swope et al., 2014). And now, in
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